We previously proposed a regime to discontinue paroxetine that, even though helpful in diminishing syndrome incidence, did not prove as successful as we had expected (2) . More recently, we have tried other strategies that proved more effective, although still not always successful. Therefore, we feel that an even slower dosage reduction should be attempted. If we are to achieve this in countries such as Spain, where only 20-mg tablets are available, manufacturers must produce new forms properly grooved to allow smaller dosages.
Our current method of discontinuing paroxetine in patients on 20-mg daily dosage is to taper it down every 20 days, as follows: Although galactorrhea induced by atypical antipsychotics, particularly risperidone, has been reported (1) (2) (3) (4) (5) , the clinical course of this adverse effects has not been adequately described. This report addresses the issue.
Case Report 1
A 31-year-old woman suffering her fourth affective episode (specifically, amitriptyline-precipitated mania) was started on risperidone 4 mg daily, along with ongoing carbamazepine 800 mg daily and lithium 900 mg daily. During the seventh week of treatment, she developed galactorrhea without other features of hyperprolactinemia. At that time, because she was found to have hypothyroidism (triiodothyronine [T 3 ], 30.0 µg/dl; thyroxine [T 4 ], 2.5µg/dl; thyroidstimulating hormone [TSH], 3.9 µU/ml), thyroxine 25µg daily was added. Simultaneously, trifluoperazine (5 mg daily) was started in place of risperidone, with which her galactorrhea and manic symptoms disappeared over 2 months.
Case Report 2
A 26-year-old woman suffering from major depression with catatonia received 7 doses of electroconvulsive therapy and then began haloperidol 5 mg daily and fluoxetine 20 mg daily. However, haloperidol was later discontinued, owing to extrapyramidal symptoms (EPS), and she began taking risperidone 2 mg daily and trihexyphenidyl 2 mg daily. Her depression and EPS improved after 3 weeks, but after 1 month of treatment, she developed galactorrhea without other hyperprolactinemic features. Her thyroid profile was normal. Consequently, her risperidone was discontinued, and within 2 weeks and while on fluoxetine, her galactorrhea remitted.
Case Report 3
A 24-year-old woman was treated with sertraline 50 mg daily and risperidone 3 mg daily for major depression with psychotic features and comorbid obsessive-compulsive disorder (OCD). During week 3, she developed galactorrhea without other hyperprolactinemic features; consequently, risperidone was stopped. She was euthyroid. Despite improvement in her symptoms, except for galactorrhea, she discontinued medications during week 6 of therapy. This led to exacerbated depressive, psychotic, and OC symptoms, and her galactorrhea persisted. She was then given sertraline 100 mg daily, along with chlorpromazine 100 mg daily, and within 2 weeks, despite only partial improvement in her psychopathology, her galactorrhea disappeared.
Case Report 4
A 34-year-old woman was taking carbamazepine 800 mg daily and haloperidol 5 mg daily to treat bipolar affective disorder diagnosed according to DSM-IV criteria. Because she developed signs of tardive dyskinesia, her haloperidol was stopped and risperidone 4 mg daily was started. After 3 months of treatment, she gradually developed amenorrhea and, 5 months later, galactorrhea. Having had a normal thyroid profile and prolactin level (that is, 1.006 ng/ml, where a normal level is < 20.0 ng/ml), she had no other hyperprolactinemic features. Owing to the distressful galactorrhea, risperidone was discontinued, and both amenorrhea and galactorrhea had vanished 1 month later.
Discussion
Although all patients had clinical galactorrhea, 3 were unwilling to have prolactin levels measured. Apart from hypothyroidism (6), fluoxetine, sertraline, fluvoxamine, and paroxetine therapy have been reported to cause galactorrhea (7-10). However, given that this patient's galactorrhea had a definite onset and offset with risperidone therapy, risperidone appears to be the main etiological agent for galactorrhea in this series.
There are 3 noteworthy observations in this report. First, galactorrhea can occur after many weeks of risperidone treatment (in 1 patient, it appeared during the seventh week). Second, even small dosages of risperidone (2 to 4 mg daily) can cause galactorrhea-a finding documented earlier (3)-but whether such effect is caused by potent D 2 antagonism, by drug interaction between risperidone and specific serotonin reuptake inhibitors, or by an idiosyncratic reaction needs investigation. Third, galactorrhea usually persists during risperidone treatment, and at times even after risperidone discontinuation. All these observations need further exploration.
Gamma Hydroxybutyrate Withdrawal in an Orthopedic Trauma Patient
Dear Editor
Gamma hydroxybutyrate (GHB) is a chemical initially developed in the 1960s
as an anesthetic agent. It is now being investigated for use in the management of narcolepsy (1) and withdrawal from opiates (2) and alcohol (3). Recreationally, it is used as a drug that induces euphoria (4), as a supplement for bodybuilders (5), and as a sexual enhancer (6) . We present a case of GHB withdrawal in a 32-year-old trauma patient.
Case Report
Mr C, a 32-year-old man with a 2-year history of panic disorder, presented to the hospital following a car accident. He did not lose consciousness but suffered multiple fractures of his pelvic girdle. His vital signs were within normal limits and his CT head and toxicology screen were negative. He did not experience any panic attacks around the time of the accident or upon admission. On his second day in hospital, his heart rate rose to 110 beats per minute. He continued to remain tachycardic, and the following day, his blood pressure rose to 170/100. On his seventh day in hospital (1 day after surgery), he began to complain of confusion. Shortly thereafter, he became agitated and began having visual and auditory hallucinations. Psychiatry was consulted and he was found to be delirious according to DSM-IV criteria (7).
Risperidone was initiated (initially 1 mg orally at night, with 0.5 mg every 2 hours as needed, then 2 mg at night the following day), with minimal effect. Collateral information suggested that chronic GHB use for anxiety (1 to 5 "capfuls" daily for 2 years) might be related to this resistance. We reviewed the literature and found that Mr C's autonomic instability and delirium were consistent with GHB withdrawal (6) . Benzodiazepines have been shown to effectively sedate patients suffering from GHB withdrawal, although the appropriate dosages remain unknown (6) . We initiated treatment with diazepam 10 mg daily on day 3 of his delirium. Twenty-four hours later, his delirium had resolved and his sleep-wake cycle returned to normal. His vital signs normalized within 3 days.
Mr C's presentation had several aspects consistent with GHB withdrawal: autonomic changes within 24 hours of discontinuing GHB use, anxiety, restlessness, confusion, delirium, visual hallucinations, and resistance to neuroleptics. However, the late onset of the delirium and the relatively quick response to diazepam are not as consistent with most reports of GHB withdrawal. Mr C's case is complicated by several factors. First, he presented as a trauma patient rather than as a patient with withdrawal symptoms, as has been seen in most case reports. Second, he had surgery and was given morphine during his hospital stay, both of which are known to cause delirium. However, it is most likely that he was experiencing GHB withdrawal, because many of his symptoms preceded both the surgery and his brief morphine use. We present this case to illustrate both the importance of considering GHB withdrawal in the differential of the causes of delirium and the need to treat the cause (in this case, GHB withdrawal was treated with diazepam), rather than attempting to manage the symptoms with a neuroleptic.
